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Dear Editor-in-Chief  
Liver cancer is considered as one of the most common cancers in the world, so 
that it is ranked fifth in males and sixth in females in the world causing high 
annual costs to patients, the health system and society (Ferlay et al., 2015). The 
worldwide mortality rate of this disease is rising annually. This disease also has 
a very high fatality, so that 88% of patients in USA (Miller et al., 2016) and 90% 
of patients in China (Zeng et al., 2015) die of this disease in the first 5 years of 
its diagnosis. Therefore, it is essential to identify factors which protect against 
this disease. The protective effects of Statins against the cardiovascular 
diseases, stroke and heart attack has been proven (Tobert, 1996). Recent 
studies have found that Statins can also have protective effects against the 
cancers (Yi, Song, Wan, Chen, & Cheng, 2017). Several meta-analysis studies 
have explored the relationship between Statin receiving and the risk of 
developing liver cancer by application of randomized clinical trials, and found 
that the use of Statins significantly reduces the risk of liver cancer.  
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The Relative Risk(RR) of liver cancer in Statin-treatment group compared with 
the control group was equal to RR=0.63 (Confidence interval (CI) of 95%, 
0.52-0.76) in research by Singh et al. (Singh, Singh, Singh, Murad, & Sanchez, 
2013), RR=0.58 (CI of 95%, 0.51-0.67) in research by Shi et al. (Shi, Zheng, Nie, 
Gong, & Cui, 2014) and RR=0.58 (CI of 95%, 0.46-0.74) in a study by Pradelli et 
al. (Pradelli et al., 2013). Recently, Changhong et al. conducted a meta-analysis 
research based on Cohort studies on the dose-response relationship between 
the Statin receiving with incidence of liver cancer.  
This study found that the relative risk of liver cancer was decrease equal to 
RR=0.86 (CI of 95%, 0.81-0.90) with an 50% increase in daily dose of received 
Statin during a year (Yi et al., 2017). Therefore, based on the results of meta-
analysis studies, which provide the highest level of scientific inferences, it can 
be argued that Statins can have protective effects against the incidence of liver 
cancer. Furthermore, according to the proof of dose-response relationship 
between the received Statin and the incidence of liver cancer, the observed 
relationship can be considered as a causal association. 
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